Drug Profile

REG 101

Alternative Names: MEDI-5884; REG101

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shionogi
Developer AstraZeneca
Class Antihyperlipidaemics; Cardiovascular therapies; Monoclonal antibodies
Mechanism of Action Cholesterol modulators; Lipase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Coronary artery disease
Discontinued Cardiovascular disorders

Most Recent Events

10 Feb 2022 Regio Biosciences plans a phase IIa trial in Peripheral arterial disorders, in the US, in the second half of 2022
04 Feb 2022 REG 101 licensed to Regio Biosciences for Peripheral artery disease
01 Feb 2022 Discontinued - Phase-I for Cardiovascular disorders (In volunteers) in USA (SC) (AstraZeneca pipeline, February 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com